{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:17:50Z","timestamp":1793891870241,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1245\/s10434-023-13370-1","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T16:02:57Z","timestamp":1680796977000},"page":"3206-3214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Landmark Series\u2014Ductal Carcinoma in Situ: The Evolution of Treatment"],"prefix":"10.1245","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-212X","authenticated-orcid":false,"given":"Amanda L.","family":"Nash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Shelley","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"issue":"4","key":"13370_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s0002-9610(03)00265-4","volume":"186","author":"MJ Silverstein","year":"2003","unstructured":"Silverstein MJ. The University of Southern California\/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186(4):337\u201343. https:\/\/doi.org\/10.1016\/s0002-9610(03)00265-4.","journal-title":"Am J Surg"},{"issue":"23","key":"13370_CR2","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","volume":"28","author":"U Rudloff","year":"2010","unstructured":"Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.26.8847.","journal-title":"J Clin Oncol"},{"issue":"23","key":"13370_CR3","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","volume":"24","author":"T Bremer","year":"2018","unstructured":"Bremer T, Whitworth PW, Patel R, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895\u2013901. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0842.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"13370_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-018-4693-2","volume":"169","author":"E Rakovitch","year":"2018","unstructured":"Rakovitch E, Gray R, Baehner FL, et al. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat. 2018;169(2):359\u201369. https:\/\/doi.org\/10.1007\/s10549-018-4693-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"13370_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jnci\/djv263","volume":"107","author":"M Worni","year":"2015","unstructured":"Worni M, Akushevich I, Greenup R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst. 2015;107(12):263. https:\/\/doi.org\/10.1093\/jnci\/djv263.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"13370_CR6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1245\/s10434-020-09534-y","volume":"28","author":"JA Margenthaler","year":"2021","unstructured":"Margenthaler JA, Dietz JR, Chatterjee A. The landmark series: breast conservation trials (including oncoplastic breast surgery). Ann Surg Oncol. 2021;28(4):2120\u20137. https:\/\/doi.org\/10.1245\/s10434-020-09534-y.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"13370_CR7","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1245\/s10434-016-5446-2","volume":"23","author":"ML Marinovich","year":"2016","unstructured":"Marinovich ML, Azizi L, Macaskill P, et al. The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2016;23(12):3811\u201321. https:\/\/doi.org\/10.1245\/s10434-016-5446-2.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"13370_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/SLA.0000000000001454","volume":"262","author":"KJ Van Zee","year":"2015","unstructured":"Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;262(4):623\u201331. https:\/\/doi.org\/10.1097\/SLA.0000000000001454.","journal-title":"Ann Surg"},{"issue":"5","key":"13370_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1200\/JCO.2016.68.3573","volume":"6","author":"M Morrow","year":"2016","unstructured":"Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Moran MS. Society of surgical oncology-American society for radiation oncology-American society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol. 2016;6(5):287\u201395. https:\/\/doi.org\/10.1200\/JCO.2016.68.3573.","journal-title":"Pract Radiat Oncol"},{"key":"13370_CR10","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1245\/s10434-007-9353-4","volume":"14","author":"TB Julian","year":"2007","unstructured":"Julian TB, Land SR, Fourchotte V, Haile SR, Fisher ER, Mamounas EP, Wolmark N. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol. 2007;14:2202\u20138. https:\/\/doi.org\/10.1245\/s10434-007-9353-4.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"13370_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.amjsurg.2016.04.019","volume":"213","author":"Chehade H El Hage","year":"2017","unstructured":"El Hage Chehade H, Headon H, Wazir U, Abtar H, Kasem A, Mokbel K. Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg. 2017;213(1):171\u201380. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.04.019.","journal-title":"Am J Surg"},{"key":"13370_CR12","doi-asserted-by":"publisher","first-page":"101880","DOI":"10.1016\/j.suronc.2022.101880","volume":"45","author":"CW Chiu","year":"2022","unstructured":"Chiu CW, Chang LC, Su CM, Shih SL, Tam KW. Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ: a systematic review and meta-analysis of real-world data. Surg Oncol. 2022;45:101880. https:\/\/doi.org\/10.1016\/j.suronc.2022.101880.","journal-title":"Surg Oncol"},{"key":"13370_CR13","unstructured":"National Comprehensive Cancer Network. NCCN Clinical practice Guidelines in Oncology. Breast Cancer Version 4.2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 6 Jan 2023"},{"issue":"2","key":"13370_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.1998.16.2.441","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Kavanah M. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441\u201352. https:\/\/doi.org\/10.1200\/JCO.1998.16.2.441.","journal-title":"J Clin Oncol"},{"issue":"1","key":"13370_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/JCO.2006.06.1366","volume":"146","author":"N Bijker","year":"2007","unstructured":"Bijker N, Meijnen P, Peterse JL. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 \u2013 a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. ACP J Club. 2007;146(1):3. https:\/\/doi.org\/10.1200\/JCO.2006.06.1366.","journal-title":"ACP J Club"},{"issue":"5","key":"13370_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/02841860600681569","volume":"45","author":"SO Emdin","year":"2006","unstructured":"Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45(5):536\u201343. https:\/\/doi.org\/10.1080\/02841860600681569.","journal-title":"Acta Oncol"},{"issue":"1","key":"13370_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(10)70266-7.","journal-title":"Lancet Oncol"},{"key":"13370_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgq039","author":"C Correa","year":"2010","unstructured":"Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Nat Cancer Inst Monogr. 2010. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq039.","journal-title":"J Nat Cancer Inst Monogr"},{"issue":"7","key":"13370_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2014.57.9029","volume":"33","author":"B McCormick","year":"2015","unstructured":"McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, White J. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709. https:\/\/doi.org\/10.1200\/JCO.2014.57.9029.","journal-title":"J Clin Oncol"},{"issue":"32","key":"13370_CR20","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.21.01083","volume":"39","author":"B McCormick","year":"2021","unstructured":"McCormick B, Winter KA, Woodward W, Kuerer HM, Sneige N, Rakovitch E, White JR. Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG oncology\/RTOG 9804. J Clin Oncol. 2021;39(32):3574\u201382. https:\/\/doi.org\/10.1200\/JCO.21.01083.","journal-title":"J Clin Oncol"},{"issue":"4","key":"13370_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J","volume":"63","author":"MD Lagios","year":"1989","unstructured":"Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989;63(4):618\u201324.","journal-title":"Cancer"},{"issue":"33","key":"13370_CR22","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","volume":"33","author":"LJ Solin","year":"2015","unstructured":"Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Davidson NE. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-Year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33(33):3938. https:\/\/doi.org\/10.1200\/JCO.2015.60.8588.","journal-title":"J Clin Oncol"},{"key":"13370_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-013-2813-6","volume":"143","author":"JS Wong","year":"2014","unstructured":"Wong JS, Chen YH, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Harris JR. Eight-year update of a prospective study of wide excision alone for small low-or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat. 2014;143:343\u201350. https:\/\/doi.org\/10.1007\/s10549-013-2813-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"13370_CR24","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1200\/JCO.20.01363","volume":"38","author":"BV Offersen","year":"2020","unstructured":"Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615\u201325. https:\/\/doi.org\/10.1200\/JCO.20.01363.","journal-title":"J Clin Oncol"},{"issue":"10215","key":"13370_CR25","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/s0140-6736(19)32514-0","volume":"394","author":"FA Vicini","year":"2019","unstructured":"Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155\u201364. https:\/\/doi.org\/10.1016\/s0140-6736(19)32514-0.","journal-title":"Lancet"},{"issue":"9378","key":"13370_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s0140-6736(03)13859-7","volume":"362","author":"J Houghton","year":"2003","unstructured":"Houghton J. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet. 2003;362(9378):95\u2013102. https:\/\/doi.org\/10.1016\/s0140-6736(03)13859-7.","journal-title":"Lancet"},{"key":"13370_CR27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","volume":"30","author":"DC Allred","year":"2012","unstructured":"Allred DC, Anderson SJ, Paik S. Adjuvant tamoxifen reduces subsequent breast cancer in women with hormone receptor-positive DCIS: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30:1268\u201373. https:\/\/doi.org\/10.1200\/JCO.2010.34.0141.","journal-title":"J Clin Oncol"},{"issue":"6","key":"13370_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","volume":"103","author":"IL Wapnir","year":"2011","unstructured":"Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Wolmark N. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Nat Cancer Inst. 2011;103(6):478\u201388. https:\/\/doi.org\/10.1093\/jnci\/djr027.","journal-title":"J Nat Cancer Inst"},{"issue":"10021","key":"13370_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","volume":"387","author":"RG Margolese","year":"2016","unstructured":"Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387(10021):849\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(15)01168-X.","journal-title":"Lancet"},{"issue":"7","key":"13370_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1940-6207.CAPR-17-0029","volume":"10","author":"LC Karavites","year":"2017","unstructured":"Karavites LC, Kane AK, Zaveri S, Xu Y, Helenowski I, Hansen N, Khan SA. Tamoxifen acceptance and adherence among patients with ductal Carcinoma In Situ (DCIS) treated in a multidisciplinary SettingTamoxifen acceptance and adherence among patients with DCIS. Cancer Prevent Res. 2017;10(7):389\u201397. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-17-0029.","journal-title":"Cancer Prevent Res"},{"issue":"10","key":"13370_CR31","doi-asserted-by":"publisher","first-page":"djv202","DOI":"10.1093\/jnci\/djv202","volume":"107","author":"JS Jeruss","year":"2015","unstructured":"Jeruss JS, Partridge AH. Use of tamoxifen by young women is influenced by fertility concerns. J Natl Cancer Inst. 2015;107(10):djv202. https:\/\/doi.org\/10.1093\/jnci\/djv202.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"13370_CR32","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/cncr.30425","volume":"123","author":"H Zhao","year":"2017","unstructured":"Zhao H, Hei N, Wu Y, Chan W, Lei X, Cameron C, Giordano SH. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer. 2017;123(6):940\u20137. https:\/\/doi.org\/10.1002\/cncr.30425.","journal-title":"Cancer"},{"issue":"19","key":"13370_CR33","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Bonanni B. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol. 2019;37(19):1629. https:\/\/doi.org\/10.1200\/JCO.18.01779.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13370_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jnci\/djy220","volume":"111","author":"MD Ryser","year":"2019","unstructured":"Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, Hwang ES. Cancer outcomes in DCIS patients without Locoregional treatment. J Natl Cancer Inst. 2019;111(9):952\u201360. https:\/\/doi.org\/10.1093\/jnci\/djy220.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"13370_CR35","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/cncr.21069","volume":"103","author":"S Elloul","year":"2005","unstructured":"Elloul S, Bukholt Elstrand M, Nesland JM, Trop\u00e9 CG, Kvalheim G, Goldberg I, Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer Interdiscip Int J Am Cancer Soc. 2005;103(8):1631\u201343. https:\/\/doi.org\/10.1002\/cncr.21069.","journal-title":"Cancer Interdiscip Int J Am Cancer Soc"},{"issue":"3","key":"13370_CR36","doi-asserted-by":"publisher","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, Partridge A. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797. https:\/\/doi.org\/10.1136\/bmjopen-2018-026797.","journal-title":"BMJ Open"},{"issue":"16","key":"13370_CR37","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","volume":"51","author":"A Francis","year":"2015","unstructured":"Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, Rea D. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51(16):2296\u2013303. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.017.","journal-title":"Eur J Cancer"},{"key":"13370_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS603","author":"C Kanbayashi","year":"2019","unstructured":"Kanbayashi C, Thompson AM, Hwang ESS, et al. The international collaboration of active surveillance trials for low-risk DCIS (LORIS LORD COMET LORETTA). J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS603.","journal-title":"J Clin Oncol"},{"key":"13370_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","volume":"152","author":"E Rakovitch","year":"2015","unstructured":"Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Paszat L. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152:389\u201398. https:\/\/doi.org\/10.1007\/s10549-015-3464-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"13370_CR40","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/jnci\/djaa179","volume":"113","author":"E Rakovitch","year":"2021","unstructured":"Rakovitch E, Sutradhar R, Nofech-Mozes S, Gu S, Fong C, Hanna W, Paszat L. 21-Gene assay and breast cancer mortality in ductal carcinoma in situ. J Natl Cancer Inst. 2021;113(5):572\u20139. https:\/\/doi.org\/10.1093\/jnci\/djaa179.","journal-title":"J Natl Cancer Inst"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13370-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T23:10:42Z","timestamp":1683846642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["13370"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13370-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amanda L. Nash declares no conflicts of interest. E. Shelley Hwang has received research support from R01 CA185138-01; U2C CA-17-035 Pre-Cancer Atlas (PCA) Research Centers; DOD BC132057; BCRF 19-074; and PRECISION CRUK Grand Challenge.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}